Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 16/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 2/20 | 0.45 |
| ▸ | BCR | P11274 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 3/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5255294 | 0.91 | SRC (0.43) | SRCABL1EGFRERBB2 | |
| SCHEMBL5253842 | 0.82 | SRC (0.60) | SRCABL1BCREGFRERBB2 | |
| SCHEMBL1893090 | 0.80 | SRC (0.62) | SRCABL1BCREGFRERBB2 | |
| SCHEMBL29590073 | 0.80 | SRC (0.62) | SRCABL1BCREGFRERBB2 | |
| SCHEMBL5255077 | 0.79 | SRC (0.74) | SRCABL1BCREGFRERBB2 | |
| SCHEMBL5251338 | 0.77 | SRC (0.77) | SRCABL1BCREGFRERBB2 | |
| SCHEMBL5740938 | 0.77 | SRC (0.58) | SRCABL1BCREGFRERBB2 | |
| SCHEMBL5740934 | 0.77 | SRC (0.58) | SRCABL1BCREGFRERBB2 | |
| SCHEMBL5251854 | 0.77 | SRC (0.72) | SRCABL1EGFRERBB2 | |
| SCHEMBL24010298 | 0.75 | SRC (0.60) | SRCABL1BCREGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1242382-B1 | TRICYCLIC PROTEIN KINASE INHIBITORS | WYETH CORP (US) | 2007-02-07 | — | — | EP | claimed |
| US-20060247217-A1 | Tricyclic protein kinase inhibitors | BERGER DAN M | 2006-11-02 | — | — | US | claimed |
| US-20040110762-A1 | Tricyclic protein kinase inhibitors | WYETH | 2004-06-10 | — | — | US | claimed |
| EP-1242382-A1 | TRICYCLIC PROTEIN KINASE INHIBITORS | Wyeth (US) | 2002-09-25 | — | — | EP | claimed |
| US-20010051620-A1 | Tricyclic protein kinase inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-12-13 | — | — | US | claimed |
| WO-2001047892-A1 | TRICYCLIC PROTEIN KINASE INHIBITORS | WYETH (US) | 2001-07-05 | — | — | WO | claimed |
| EP-1242382-B1 | TRICYCLIC PROTEIN KINASE INHIBITORS | WYETH CORP (US) | 2007-02-07 | — | — | EP | disclosed |
| US-20060247217-A1 | Tricyclic protein kinase inhibitors | BERGER DAN M | 2006-11-02 | — | — | US | disclosed |
| US-7105531-B2 | Tricyclic protein kinase inhibitors | WYETH (US) | 2006-09-12 | — | — | US | disclosed |
| US-20040110762-A1 | Tricyclic protein kinase inhibitors | WYETH | 2004-06-10 | — | — | US | disclosed |
| US-6638929-B2 | Compounds containing nicotinonitrile rings; anticarcinogenic and -tumor agents; polycystic kidney disease and colonic polyps; antiproliferative agents; angiogenesis inhibitors; restenosis; atherosclerosis; angiofibromas; hemangiomas; | WYETH | 2003-10-28 | — | — | US | disclosed |
| US-20030185754-A1 | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | GENSET, S.A. (FR) | 2003-10-02 | — | — | US | disclosed |
| US-20030166554-A1 | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | GENSET, S.A. (FR) | 2003-09-04 | — | — | US | disclosed |
| EP-1242382-A1 | TRICYCLIC PROTEIN KINASE INHIBITORS | Wyeth (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20010051620-A1 | Tricyclic protein kinase inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-12-13 | — | — | US | disclosed |
| WO-2001047892-A1 | TRICYCLIC PROTEIN KINASE INHIBITORS | WYETH (US) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110762-A1 | Tricyclic protein kinase inhibitors | CDK1, CDKN1A, CDK2 | SRC 104/4885KDM4E 1644/4885ALDH1A1 3285/4885 |
| US-20060247217-A1 | Tricyclic protein kinase inhibitors | CDK1, CDKN1A, CDK2 | SRC 117/4885KDM4E 1432/4885ALDH1A1 3511/4885 |
| US-20030185754-A1 | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | DDO, DAO, XDH | SRC 3071/4885KDM4E 3290/4885ALDH1A1 467/4885 |
| US-20010051620-A1 | Tricyclic protein kinase inhibitors | CDK1, CHEK1, ABL1 | SRC 134/4885KDM4E 1527/4885ALDH1A1 4120/4885 |
| US-20030166554-A1 | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | DDO, DAO, XDH | SRC 3071/4885KDM4E 3290/4885ALDH1A1 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.